Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 2/5 criteria met.
- ✅ Price trend passed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 39.13%
Price change 2019 → 2020: 193.75%
Price change 2020 → 2021: -42.77%
Price change 2021 → 2022: 57.99%
Price change 2022 → 2023: -38.59%
Price change 2023 → 2024: 583.91%
Price change 2024 → 2025: -2.02%
Price change 2025 → 2026: -4.57%
Price change 2026 (year to date): -4.74%
Financial growth
Revenue CAGR (8 years): -100.00%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.03
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -14.96
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 36.73% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="SMMT" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Summit Therapeutics Inc. | – | 0.03 | – | 🔒 |
| Tempus AI, Inc. | – | 2.70 | +65.4 % | – |
| bioMérieux S.A. | 23.5 | 0.11 | +7.6 % | ★ 4/5 |
| Ipsen S.A. | 25.6 | 0.20 | +7.9 % | – |
| Bio-Rad Laboratories, Inc. | 41.1 | 0.20 | +2.0 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Summit Therapeutics Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2017 | 23.1 m | -37.7 m | -163.1 % | n/a |
| 2018 | 74.5 m | 13.0 m | 17.5 % | +222.5 % |
| 2019 | 808,413 | -31.6 m | -3,903.4 % | -98.9 % |
| 2020 | 860,000 | -52.7 m | -6,127.6 % | +6.4 % |
| 2021 | 1.8 m | -88.6 m | -4,897.8 % | +110.3 % |
| 2022 | 704,295 | -78.8 m | -11,185.9 % | -61.1 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Summit Therapeutics Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 53.2 m | 284 m | 147 m | 330 m | 713 m |
| Total Debt | 2.1 m | 423 m | 84.0 m | 5.8 m | 20.9 m |
| Net Debt | -51.2 m | 139 m | 27.4 m | -78.0 m | -204 m |
| Equity | 61.7 m | 103 m | 61.5 m | 311 m | 659 m |
| Total assets | 84.0 m | 541 m | 161 m | 348 m | 751 m |
| Operating cash flow | -53.8 m | -33.9 m | -60.7 m | -114 m | -323 m |
| Investments (capex) | 226,830 | 508,681 | 101,293 | 111,073 | 657,000 |
| Free cash-flow | -54.0 m | -34.4 m | -60.8 m | -114 m | -324 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
Summit Therapeutics Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Summit Therapeutics Inc. | 11.3 bn | n/a | 0.0 % |
| Spero Therapeutics, Inc. SPRO | 58.3 m | 4.2 | 14.4 % |
| Acurx Pharmaceuticals, Inc. ACXP | 5.8 m | n/a | 0.0 % |
| ImmunityBio, Inc. IBRX | 6.4 bn | n/a | -310.2 % |
| Palisade Bio, Inc. PALI | 201 m | n/a | 0.0 % |
| Seres Therapeutics, Inc. MCRB | 14.3 m | n/a | 721.9 % |
| Traws Pharma, Inc. TRAW | 3.9 m | n/a | 328.7 % |
| Enanta Pharmaceuticals, Inc. ENTA | 320 m | n/a | -125.4 % |
| Sector median (Nasdaq) | 20.8 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Summit Therapeutics Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Average target over the last 3 months: 28.70 USD (7 targets).
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 3.7 m | -794 m | -1.16 (-1.42 / -1.02) | n/a | 9 |
| 2027 | 59.5 m | -947 m | -1.13 (-1.36 / -0.95) | n/a | 8 |
| 2028 | 581 m | -677 m | -0.69 (-1.18 / 0.22) | n/a | 7 |
Amounts in GBP, the reporting currency.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Rating changes (12 months)
| Date | Firm | Before | After |
|---|---|---|---|
| 01/10/2026 | Barclays | Equal Weight | Equal Weight |
| 29/09/2026 | Citigroup | Buy | Buy |
| 23/09/2026 | HC Wainwright & Co. | Neutral | Neutral |
| 09/09/2026 | Jefferies | Hold | Buy |
| 26/08/2026 | HC Wainwright & Co. | Neutral | Neutral |
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Summit Therapeutics Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 04/11/2026 | -0.26 | -0.28 | n/a |
| 23/07/2026 | -0.28 | -0.27 | n/a |
| 30/04/2026 | -0.24 | -0.33 | n/a |
| 23/02/2026 | -0.29 | -0.10 | n/a |
| 20/10/2025 | -0.31 | -0.18 | n/a |
| 11/08/2025 | -0.76 | -0.09 | n/a |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Summit Therapeutics Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| State Street | 19.1 m | 278 m | 0.0 % | +171.4 % | 2026Q2 |
| Vanguard Group | 11.2 m | 195 m | 0.0 % | -1.8 % | 2025Q4 |
| Fidelity | 10.0 m | 146 m | 0.0 % | -7.5 % | 2026Q2 |
| BlackRock | 9.5 m | 139 m | 0.0 % | -1.3 % | 2026Q2 |
| Goldman Sachs | 4.5 m | 65.8 m | 0.0 % | +1,352.5 % | 2026Q2 |
| T. Rowe Price | 3.9 m | 56.7 m | 0.0 % | -53.0 % | 2026Q2 |
| Point72 Asset Management | 3.7 m | 53.9 m | 0.1 % | +371.5 % | 2026Q2 |
| Citadel Advisors | 3.5 m | 50.3 m | 0.0 % | +681.3 % | 2026Q2 |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Summit Therapeutics Inc.
What is the Summit Therapeutics Inc. share price?
Latest recorded price: 14.15 USD on 13/11/2026, for a market cap of 11.3 bn USD.
What is the revenue of Summit Therapeutics Inc.?
704,295 USD for fiscal year 2022, with net income of -78.8 m USD (net margin -11,185.9 %).
When does Summit Therapeutics Inc. report its next earnings?
The next release is expected on 22/02/2027. EPS expected by analysts: -0.34.
What do analysts say about Summit Therapeutics Inc.?
Out of 23 analysts: 15 buy or strong buy, 8 hold, 0 sell or strong sell. Average price target: 33.13 USD, i.e. +134.1 % from the share price.
Is Summit Therapeutics Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US86627T1088).
How many employees does Summit Therapeutics Inc. have?
159 full-time employees according to the latest published profile.
Who runs Summit Therapeutics Inc.?
Robert W. Duggan is the company's chief executive.
Which large funds own Summit Therapeutics Inc.?
As of 2026Q2, among the large funds tracked: State Street, Vanguard Group, Fidelity, BlackRock, Goldman Sachs.